Brief: BiomX Provides A Program Update And Announces New FDA Feedback Potentially Expanding BX004 Development Pathways
17/10/2025 13:32
Oct 17 (Reuters) - Biomx Inc PHGE.A: BIOMX PROVIDES A PROGRAM UPDATE AND ANNOUNCES NEW FDA FEEDBACK POTENTIALLY EXPANDING BX004 DEVELOPMENT PATHWAYS BIOMX INC - PHASE 2B RESULTS EXPECTED Q1 2026 BIOMX INC - ADDRESSES FDA QUERIES ON NEBULIZER FOR BX004 BIOMX INC - FDA RECOGNIZES UNMET NEED FOR CF THERAPIES BIOMX INC: FDA HAS NOT RAISED ANY CONCERN REGARDING BX004 DRUG PRODUCT Source text: ID:nGNX7kYtzJ Further company coverage: PHGE.A
Recent news on Tessera Defense and Homeland Security
See all newsBrief: Tessera Defense & Homeland Security - Enters $5 Million Revolving Credit Agreement With Mandragola On Oct 5, 2026 - SEC Filing
Brief: Biomx - Announces One-For-Ten Reverse Stock Split Of Common Stock - SEC Filing
Brief: Biomx And Water.Io Agree To Updated Zorronet Acquisition Terms
Brief: BiomX - May Offer And Sell Up To $9.10 Million Of Common Stock Through Wainwright - SEC Filing
Brief: Biomx Provides Update On Defense Technology Portfolio And Growth Strategy